article Open AccessTop 1% cited

Apixaban versus Warfarin in Patients with Atrial Fibrillation

New England Journal of Medicine · 2011 · Vol. 365(11) · pp. 981–992

Christopher B. Granger✉(Duke University)John H. Alexander(Duke Medical Center)John J.V. McMurrayRenato D. Lópes(Clinical Research Institute)Elaine M. Hylek(University Medical Center)Michael G. Hanna(Bristol-Myers Squibb (United States))Hussein R. Al‐Khalidi(Clinical Research Institute)Jack Ansell(Lenox Hill Hospital)Dan Atar(Oslo University Hospital)Álvaro Avezum(Instituto Dante Pazzanese de Cardiologia)M. Cecilia Bahit(Estudios Clínicos Latinoamérica)Rafael Díaz(Estudios Clínicos Latinoamérica)J. Donald Easton(University of California, San Francisco)Justin A. Ezekowitz(University of Alberta)Greg Flaker(University of Missouri Health System)David García(University of New Mexico)Margarida Geraldes(Bristol-Myers Squibb (United States))Bernard J. Gersh(Mayo Clinic in Arizona)Golitsyn Sp(Institute of Experimental Cardiology)Shinya Goto(Tokai University)Antonio G. Hermosillo(Instituto Nacional de Cardiología)Stefan H. Hohnloser(Goethe University Frankfurt)John D. Horowitz(University of Adelaide)Puneet Mohan(Bristol-Myers Squibb (United States))Petr Janský(University Hospital in Motol)Basil S. Lewis(Carmel Medical Center)José López‐Sendón(Hospital Universitario La Paz)Prem Pais(St.John's Medical College Hospital)Alexander ParkhomenkoFreek W.A. Verheugt(OLVG)Jun Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College)Lars Wallentin(Uppsala University)

View via DOI Full-text PDF

Abstract

In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. (Funded by Bristol-Myers Squibb and Pfizer; ARISTOTLE ClinicalTrials.gov number, NCT00412984.).

Atrial Fibrillation Management and Outcomes Cardiac Arrhythmias and Treatments Antiplatelet Therapy and Cardiovascular DiseasesApixabanAtrial fibrillationWarfarinCardiologyMedicineInternal medicineRivaroxaban

MeSH terms

AgedAnticoagulantsAtrial FibrillationDouble-Blind MethodFemaleFollow-Up StudiesHemorrhageHumansMaleMiddle AgedPyrazolesPyridonesThromboembolismWarfarinTreatment Outcome

Citations

8,827

FWCI

383.43

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Stroke Risk Factors, Genetics, and Prevention